Production & Sales

Cerecor to acquire TRx Pharmaceuticals

Cerecor has entered into an agreement to TRx Pharmaceuticals and its subsidiary Zylera Pharmaceuticals.

Cardinal to divest drug distribution business in China to Shanghai Pharma

Cardinal Health, an Ohio-based health care services company has signed a deal to divest its drug distribution business in China to Shanghai Pharmaceuticals (Shanghai Pharma) for $557m.

Torrent to acquire Unichem’s branded business of India and Nepal

Torrent Pharmaceuticals has entered into a definitive binding agreement with Unichem to acquire its branded business of India and Nepal (India business) for a consideration of Rs3600 crores.

Novartis to buy nuclear medicine firm Advanced Accelerator Applications for $3.9bn

Novartis has agreed to acquire French radiopharmaceutical company Advanced Accelerator Applications (AAA) for $3.9bn to strengthen its oncology presence.

Clinigen acquires Japanese unlicensed medicines supplier

Clinigen Group has acquired International Medical Management (IMMC), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.

Amneal to acquire Impax to expand generics business in US

Amneal Pharmaceuticals has agreed to buy Impax Laboratories in an all-stock deal to create a diversified pharmaceutical firm that is expected to become the fifth largest generics business in the US.

Catalent to acquire Indiana-based CDMO Cook Pharmica for $950m

Catalent has agreed to acquire Indiana-based contract development and manufacturing organization (CDMO) Cook Pharmica for $950m to consolidate its position in the bio-pharma sector.

Bioverativ, Bicycle Therapeutics to develop therapies for hemophilia and sickle cell disease

Bioverativ and Bicycle Therapeutics have announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease.

Aptevo Therapeutics to sell hyperimmune commercial products

Aptevo Therapeutics has agreed to sell its three marketed hyperimmune products, WinRho SDF, HepaGam B, and VARIZIG, to Saol Therapeutics for total consideration of up to $74.5m.